Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Motexafin Gadolinium with WBRT and SRS Boost for Brain Metastases
NCT00121420Phase 2Terminated
- Sponsor
- Pharmacyclics
- Modality
- Orthosteric Ligands, Light/Condition-Responsive Prodrugs
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of motexafin gadolinium in brain metastases, sponsored by Pharmacyclics. Primary endpoint: Rate of irreversible Grade 3 or any Grade 4 or 5 neurologic radiation toxicities. Status: terminated.
02
Drugs
motexafin gadolinium
03
Conditions
brain metastases
Beyond the preview
Go deeper on NCT00121420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00121420.